For the first time, a study has confirmed that using the HIV-prevention pill can effectively thwart the virus in uninfected men by a significant amount, a finding that patient activists argue should spur public health officials to more aggressively push for wider access to the medicine.

By giving men the PrEP pill on a rapid and targeted basis, the HIV diagnosis rate fell by 25 percent in just one year, from 295 cases in the fall of 2016 to 221 cases the following year, according to the study, which was published in The Lancet HIV journal.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

  • Cytodyn /Pro 140 Puts this Drug to SHAME. Whe have absolutely no SIDE EFFECTS. GILEAD SHOULD BUY US OUT. WE ALSO HAVE A CURE FOR VARIOUS CANCERS

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy